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Abstract: Treatment outcome data generated in prospective trials are intrinsically biased due to necessary selection criteria. 
Therefore the results obtained may not reﬂ  ect the actual impact of current treatment options for an unselected general 
population. We analysed the treatment modalities and the outcome in 212 consecutive patients with non small cell lung 
cancer stages IIIB and IV who were seen in a community based oncology group practice between 6/1995 and 6/2006. 
93 presented with stage IIIB and 119 with stage IV. Chemotherapy was given to 194/212 patients (92%), 114 patients (54%) 
received palliative radiation at one point during treatment. Treatment consisted of chemotherapy only in 86 patients (40%) 
and radiation only in 6 patients. 12 patients received best supportive care only. Patients with stage IIIB have survival rates 
at 12, 24 and 36 months of 64%, 27% and 21% respectively and for patients with stage IV the survival rates at 12, 24 and 
36 months are 40%, 19% and 11% respectively. The median survival for stages IIIB and IV is 16 and 11 months respectively. 
In a multivariate analysis incorporating the factors stage (IIIB vs. IV), age ( 70 vs.  70 years) and performance status 
(WHO 0/1 vs. 2/3) only stage and performance status were independent factors for survival. These retrospective data con-
cerning analysis of survival , response rates and toxicity in a community setting conﬁ  rm published results of phase II-III 
studies and indicate that results generated in prospective trials can be transferred into routine care.
Keywords: cohort study, chemotherapy, survival rate, elderly, patient selection, outcome
Introduction
Chemotherapy with platinum based regimen has moderately increased the median survival for patients 
(pts) with advanced non small cell lung cancer (NSCLC) to 6–9 months.
1–7 In recent years newer 
substances as gemcitabine, vinorelbine, taxanes and pemetrexed have widened the treatment options 
for this patient cohort and resulted in a median survival time of around 10 months.
8–13 New drugs as 
erlotinib targeting the EGFR
14 or bevacizumab targeting VEGF
15 have further improved the prognosis 
for these patients. However treatment outcome data generated in prospective trials are intrinsically 
biased by scientiﬁ  cally necessary selection criteria. Therefore results obtained in clinical trials may not 
reﬂ  ect the impact of current treatment options for a less selected population. Little data exist how results 
of trials are incorporated in routine care in oncology and what outcome is achieved. As part of an internal 
quality control initiative we evaluated the treatment modalities and the outcome of 212 consecutive pts. 
with advanced NSCLC who were treated in a community based oncology group practice.
Patients and Methods
Study population
We conducted a retrospective study of all consecutive patients with advanced NSCLC treated between 
June 1995 and June 2006 in a community based oncology group practice in Koblenz, Germany. This 
time window included patients with access to taxanes, gemcitabine, vinorelbine, pemetrexed and erlotinib 
and no access to bevacizumab treatment. The observation was terminated in June 2007.
The primary endpoint was overall survival and secondary endpoints were response rates and 
toxicity.
All patients had given written informed consent to process their anonymous clinical data for scientiﬁ  c 
purpose. The study was conducted in accordance with the declaration of Helsinki.64
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Data collection and measurement
Patients were identiﬁ  ed by searching the group 
practice’s electronic ﬁ  les for relevant codes of the 
International Classification of Diseases tenth 
Revision. Trained study nurses used a computerised 
data collection tool to extract the relevant data from 
electronic records (demographic data, laboratory 
data, results of imaging studies) and medical charts 
(clinical information from each visit for every 
patient during the treatment and observation 
period). Survivorship and cause of death was 
ascertained using information from the medical 
charts if terminal care was provided by the 
oncologists or from the charts of external terminal 
care givers (primary care physicians, hospitals).
Chemotherapy regimen
Chemotherapy regimen used in this cohort included 
cis-platinum/etoposide, gemcitabine mono, vinorel-
bine mono, gemcitabine/vinorelbine, paclitaxel/
carboplatin weekly, taxotere/carboplatin weekly, 
pemetrexed, and erlotinib. Patients treated with 
radiation and concurrent chemotherapy received 
either cis-platinum/etoposid or a platinum compound 
only. The choice of chemotherapy and the sequence 
of protocols was at the discretion of each physician.
Evaluation of performance status, 
toxicity and response
Performance status was evaluated using ECOG 
criteria.
Toxicity was classiﬁ  ed according to World Health 
Organization criteria by clinical investigators at 
each cycle for each patient. For each patient and 
each type of toxicity, the worst degree of toxicity 
experienced throughout the treatment was used for 
the analysis.
Responses and progression were evaluated 
using Response Evaluation Criteria in Solid 
Tumours.
16 Responses were evaluated after three 
to six treatment cycles . The best response for each 
patient was used for the analysis. When evaluating 
patients, a complete response was deﬁ  ned as the 
disappearance of all known sites of disease; a 
partial response was deﬁ  ned as a decrease of 50% 
or more in the sum of the products of the largest 
perpendicular diameters of measurable lesions, no 
new lesions, and no progression of any lesion; 
stable disease was deﬁ  ned as a decrease of less 
than 50% or an increase of less than 25% in the 
sum of the products of the largest perpendicular 
diameters of measurable lesions and no new 
lesions; and progressive disease was deﬁ  ned as an 
increase of 25% or more in the size of one or more 
measurable lesions, or a new lesion. Patients who 
stopped treatment because of toxicity or refusal 
Table 1. Patients characteristics.
Number of 
patients 
(%) (n = 212)
Male/Female 155 (73%)/57 (27%)
Median age (range) 64 (37–87) years
 Patients    70 years 56 (26%)
Performance 
Status (ECOG)
Pts. with 
palliative 
treatment
Pts. 
with 
BSC
  0 24 (12%) 0 (0%)
  1 96 (48%) 0 (0%)
  2 73 (37%) 6 (50%)
  3 7 (4%) 6 (50%)
UICC Stage
 IIIB 93  (44%)
   −IIIB with pleural 
effusion
14/93 (15%)
 IV 119  (56%)
Histology
  Adeno carcinoma 114 (54%)
   Squamos cell 
carcinoma
66 (31%)
  Large cell carcinoma 14 (7%)
 Alveolar  carcinoma 2  (1%)
  Other histology/n.e. 16 (8%)
All patients
Radiotherapy only
Erlotinib treatment Erlotinib treatment
only
Chemotherapy 
Chemotherapy Chemotherapy 
Best supportive care
n = 212
n = 12 n = 6
n = 86
n = 6 n = 4
n = 108
n = 194
(alive = 6, dead = 192, LFU* = 14)
(dead = 11, LFU = 1) (alive = 6, dead = 175, LFU = 13)
(alive = 2, dead = 77, LFU = 7)
(dead = 6) (dead = 4)
(alive = 2, dead = 98, LFU = 6)
(dead = 6)
(*LFU = Lost to follow up)
plus any radiotherapy
Figure 1. Allocation of treatment modalities to all patients.65
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before restaging procedures were defined as 
‘non-evaluated.’
Statistical Analysis
All statistical analyses were performed using the 
SPSS program (SPSS Inc. Chicago, IL, U.S.A.).
Estimates of survival were calculated and 
plotted according to the method of Kaplan and 
Meier and compared using the log rank test. 
Patients who were lost to follow up were censored 
at the last documented contact. Qualitative param-
eters were analysed by chi-square test. Multivari-
ate analysis was done using the Cox model.
We evaluated the cohort of patients   70 years 
separately and compared the parameters chemo-
therapy regimen, toxicity, response rates and overall 
survival with the cohort of patients   70 years.
Results
Demographic and disease related data
212 consecutive patients were seen between 6/95 
and 6/2006. Patients characteristics are listed in 
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Figure 2. Number of chemotherapy protocols.
Table 1. Median age was 64 years (range 37–87) and 
56 pts (26%) were  /= 70 years old. 93 (44%) had 
stage III B disease, and 119 (56%) stage IV disease. 
54% had an adeno carcinoma , 31% squamous cell 
carcinoma, 7% large cell carcinoma, 1% alveolar 
carcinoma and 8% undifferentiated carcinomas.
Treatment regimens and sequences
The treatment applied to this cohort of patients is 
outlined in Figure 1. Chemotherapy was given to 
194/212 patients (92%), 114 patients (54%) received 
palliative radiation at one point during treatment. 
Treatment consisted of chemotherapy only in 
86 patients (40%) and radiation only in 6 patients. 
12 patients received best supportive care only due 
to impaired performance status (WHO = 3) 194/212 
patients (92%) received a median of 2 (range 1–7) 
different chemotherapy protocols (Fig. 2).
First line treatment consisted of a platinum/
taxane regimen in 95 pts (49%), a platinum/
non-taxane combination in 35 pts (18%), a 
non-platinum combination in 22 pts (11%) and 
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Figure 3. Chemotherapy regimens of lines 1 to 3 (all patients).
Figure 3.1. Chemotherapy regimens of lines 1 to 3 (patients   70 
years).
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Figure 3.2. Chemotherapy regimens of lines 1 to 3 (patients   70 
years).
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a monotherapy (gemcitabine,vinorelbine or 
docetaxel) in 42 pts (22%).
126/194 pts (65%) received a second line 
treatment and a third line chemotherapy was given 
to 75/194 pts (39%) (Fig. 3). The analysis of the 
cohorts of pts   70 versus  /= 70 years revealed 
that younger patients more often received platinum 
based combinations and older patients received 
more often monotherapies (Figs. 3.1 and 3.2.). 
10 (5%) pts were treated with erlotinib.
Toxicity
Toxicity data of each treatment line are shown in 
Table 2. Grade 3/4 toxicity was seen in 19/194 pts 
(10%) receiving ﬁ  rst line therapy. Main toxicities 
were haematological toxicity and neuropathy. 
There was a trend to increased haematological 
toxicity and neurotoxicity in subsequent treatment 
lines. When analysing the cohort of patients  /= 
70 years, no increased toxicity was seen (Tables 
2.1 and 2.2).
Response and survival
Response rates to ﬁ  rst line treatment and consecutive 
treatment lines are shown in Table 3.
Objective responses (complete and partial 
responses) were seen in 29%, 28% and 24% 
patients to ﬁ  rst, second and third line treatment 
respectively. When comparing response rates by 
age or performance status a signiﬁ  cant higher 
response rate was observed in patients   70 years 
in all treatment lines (Table 3.1) and in patients 
with good performance status (ECOG 0/1 vs. 2/3) 
(Table 4).
At the end of the observation time 192/212 pts 
(91%) had died. 157/212 pts (82%) died of tumour 
related causes. 1/212 pts died of therapy related 
toxicity. In 13/212 pts (7%) the cause of death was 
not tumour related and in 21/212 pts (11%) the 
exact cause could not be evaluated. With a mini-
mum follow up of 12 months the median survival 
of patients with stages IIIB and IV is 16 and 11 
months respectively (p = 0,014). The overall 
Table 2. Toxicity WHO grade 3/4 (all patients).
1st-line 
therapy
19/194 pts 
(10%)
2nd-line 
therapy
11/126 pts 
(9%)
3rd-line 
therapy
9/75 pts 
(12%)
Haematotoxicity 3 (1.5%) 3 (2%) 4 (5%)
Neuropathy 4 (2%) 4 (3%) 5 (7%)
Mucotoxicity 0 (0%) 1 (1%) 0 (0%)
Nausea/Emesis 7 (4%) 2 (1.5%) 0 (0%)
Diarrhea 3 (1.5%) 1 (1%) 0 (0%)
Others 5 (2.5%) 5 (4%) 1 (1%)
Table 2.1. Toxicity WHO grade 3/4 (patients   70 
years).
1st-line 
therapy
16/146 pts 
(11%)
2nd-line 
therapy
8/98 pts 
(8%)
3rd-line 
therapy
8/58 pts 
(14%)
Haematotoxicity 2 (1%) 2 (2%) 4 (7%)
Neuropathy 4 (3%) 2 (2%) 5 (9%)
Mucotoxicity 0 (0%) 1 (1%) 0 (0%)
Nausea/Emesis 6 (4%) 2 (2%) 0 (0%)
Diarrhea 2 (1%) 1 (1%) 0 (0%)
Others 5 (3%) 5 (5%) 0 (0%)
Table 2.2. Toxicity WHO grade 3/4 (patients   70 
years).
1st-line 
therapy
3/48 pts 
(6%)
2nd-line 
therapy
3/28 pts 
(11%)
3rd-line 
therapy
1/17 pts 
(6%)
Haematotoxicity 1 (2%) 1 (3.5%) 0 (0%)
Neuropathy 0 (0%) 2 (7%) 0 (0%)
Mucotoxicity 0 (0%) 0 (0%) 0 (0%)
Nausea/Emesis 1 (2%) 0 (0%) 0 (0%)
Diarrhea 1 (2%) 0 (0%) 0 (0%)
Others 0 (0%) 0 (0%) 1 (6%)
Table 3. Overall response (all patients).
1st-line 
therapy
n = 194
2nd-line 
therapy
n = 126
3rd-line 
therapy
n = 75
CR 4 (2%) 1 (1%) 0 (0%)
PR 52 (27%) 34 (27%) 18 (24%)
SD 55 (28%) 28 (22%) 19 (25%)
PD 47 (24%) 45 (36%) 25 (33%)
Undetermined* 36 (19%) 18 (14%) 13 (17%)
*Reasons for undetermined response were termination or change 
of chemotherapy regimens because of toxicity, refusal or lost to 
follow up.67
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survival rates at 12, 24, 36 and 60 months for stage 
IIIB are 64%, 27%, 21% and 6% respectively and 
for stage IV 40%, 19%, 11% and 5% respectively 
(Fig. 4). No signiﬁ  cant difference in survival was 
seen in patients  /= 70 years (median survival for 
stage IIIB and IV is 15 and 10 months respectively) 
as compared to younger patients (median survival 
for stage IIIB and IV is 17 and 12 months respec-
tively) (Figs. 4.1 and 4.2). Patients with a good 
performance status (ECOG 0/1) had a median 
survival of 15 months as compared to 11 months 
for patients with an impaired performance status 
(ECOG 2/3) (p = 0,001) (Fig. 5).
In a multivariate analysis of the factors age, 
performance status and stage only performance 
status and stage were independent factors 
inﬂ  uencing survival (Table 5).
Discussion
The therapeutic arsenal for the treatment of 
advanced NSCLC has signiﬁ  cantly improved over 
the last years. The introduction of new effective 
chemotherapy agents as taxanes, gemcitabine, 
vinorelbine, pemetrexed
8–13 and targeted drugs as 
erlotinib
14 and bevazucimab
15 has increased the 
median survival to  12 months in prospective 
randomized phase II/III studies . A number of stud-
ies demonstrated the efﬁ  cacy of second and third-
line protocols.
9–14 However the results obtained in 
clinical trials are biased due to the scientiﬁ  cally 
necessary strict inclusion criteria, which exclude 
e.g. elderly, patients with an impaired performance 
status or patients with signiﬁ  cant comorbidity. 
There are only few data about the impact of new 
treatment options and their use in routine care in 
oncology when serving a population with higher 
median age, compromised performance status and 
comorbitidy in a community based setting. In most 
clinical trials in advanced NSCLC the upper age 
limit is 75 years and the median age is around 64 
years. The median age of patients at ﬁ  rst diagnosis 
of NSCLC in Germany is 68 years and 30% are 
 75 years old demonstrating that a considerable 
proportion of patients would have been not eligible 
for a number of trials just due to age. There is 
however growing evidence that older patients have 
similar beneﬁ  ts from palliative chemotherapy and 
from newer substances as do younger patients with 
NSCLC. The ELVIS and the MILES trial
17,18 and 
the West Japan Thoracic Oncology Group Trial 
WJTOG 9904
19 were designed exclusively for 
patients  70 years and reported a median survival 
of 7, 9 and 14, 3 months respectively. The Eastern 
Cooperative Oncology Group reported for the 
ﬁ  rst time in a randomised trial the results for 
patients  70 years with NSCLC treated with 
cis-platinum based protocols.
20 In this trial and in 
subset analyses in several other studies which 
enrolled elderly patients this cohort had similar 
response rates and survival data as younger 
patients.
21,22 Recently Asmis et al
23 retrospectively 
Table 3.1. Overall response (patients   70 vs patients   70 years).
1st-line therapy 2nd-line therapy 3rd-line therapy
pts   70
(n = 146)
pts   70
(n = 48)
pts   70
(n = 98)
pts   70
(n = 28)
pts   70
(n = 58)
pts   70
(n = 17)
CR 4 (3%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%)
PR 43 (29%) 9 (19%) 29 (30%) 5 (18%) 15 (26%) 3 (18%)
SD 38 (26%) 17 (35%) 22 (22%) 6 (21%) 11 (19%) 8 (47%)
PD 36 (25%) 11 (23%) 35 (36%) 10 (36%) 21 (36%) 4 (24%)
Undetermined* 25 (17%) 11 (23%) 11 (11%) 7 (25%) 11 (19%) 2 (12%)
*Reasons for undetermined response were termination or change of chemotherapy regimens because of toxicity, refusal or lost to follow up.
Table 4. Overall response of 1st-line therapy (ECOG 
0/1 vs. ECOG 2/3).
ECOG 0/1 ECOG 2/3
n = 117 n = 77
CR 3 (3%) 1 (1%)
PR 35 (30%) 17 (22%)
SD 40 (34%) 15 (19%)
PD 26 (22%) 21 (27%)
Undetermined* 13 (11%) 23 (30%)
*Reasons for undetermined response were termination or change of 
chemotherapy regimens because of toxicity, refusal or lost to follow up.68
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Stage IIIB
UICC IIIB
UICC IV
Median survival:
Range:
17 months
(1–110)
1st year 64% 41%
27%
11%
18%
20%
7% 7%
2nd year
3rd year
5th year
(1–108)
12 months
Overall survival rates:
Stage IV
p = 0.05
100 125 75 50 25 0
0.0
0.5
1.0
Months
Figure 4.1. Overall survival by stage (patients   70 years).
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(1–110)
1st year 64% 40%
19%
11%
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21%
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11 months
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Months
p = 0.014
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Figure 4. Overall survival by stage (all patients).69
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Stage IIIB
UICC IIIB
UICC IV
Median survival:
Range:
15 months
(2–58)
1st year 64% 38%
23%
8%
0%
28%
24%
0%
70 60 40 50 30 20 10 0
0.0
0.5
1.0
2nd year
3rd year
5th year
(1–49)
10 months
Overall survival rates:
Months
p = 0.089
Stage IV
Figure 4.2. Overall survival by stage (patients   70 years).
Median survival:
Range:
15 months
1st year. 57% 43%
27% 16%
20%
10%
7%
2%
2nd year.
3rd year.
5th year.
(1−58) (1−110)
11 months
Overall survival rates:
p = 0.001
100 125 75 50 25 0
0.0
0.5
1.0
Months
ECOG 0/1
ECOG 0/1
ECOG 2/3
ECOG 2/3
Figure 5. Overall survival by performance status (ECOG 0/1 vs 2/3).
analysed age and comorbidity as prognostic factors 
for survival in two prospective trials of the National 
Cancer Institute of Canada Clinical Trials Group 
in NSCLC. In these trials comorbidity was an 
independent factor while age was not.
With a median age of 65 years and a range up 
to 87 years the present study analysed a cohort 
representing the general population of patients with 
NSCLC except for a possible referral bias. The 
median and absolute number of chemotherapy 
protocols applied to each patient demonstrates that 
available options were incorporated in the treat-
ment strategy. Toxicity was acceptable and in the 
expected range for the applied protocols. The 
results demonstrate that this group does beneﬁ  t 
from newer chemotherapy agents. The median 70
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Table 5. Multivariate analysis of survival by stage, 
performance status and age
Hazard ratio 95% CI p
Stage
 IIIB 1
 IV 1,539 1,149–2,061 0,004
ECOG
 0/1 1
 2/3 1,759 1,302–2,376  0,001
Age
   70 1
   70 1,015 0,732–1,407 0,929
survival of 16 months for stage IIIB and 12 months 
for stage IV in this cohort is well in the range 
reported for phase III study populations. With 15 
and 10 months for stage IIIB and IV respectively 
the median survival of elderly patients in the cur-
rent study is comparable to the data generated in 
recently published prospective trials.
19,21,22 As in 
these reported clinical trials age was not a 
signiﬁ  cant factor for survival while performance 
status and stage were signiﬁ  cant factors.
These retrospective data concerning analysis of 
survival, response rates and toxicity for patients 
with advanced NSCLC in a community setting 
conﬁ  rm the results of phase III studies.
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